OncoMatch/Prostate Cancer/AR (Androgen Receptor)
Prostate CancerAR (Androgen Receptor) Clinical Trials
Androgen receptor (AR) amplification, splice variant expression (AR-V7), and ligand-binding domain mutations drive resistance to AR-targeted therapy in castration-resistant prostate cancer. AR-V7 positivity predicts resistance to enzalutamide and abiraterone but retained sensitivity to taxane chemotherapy. Trials investigate next-generation AR degraders and proteolysis-targeting chimeras (PROTACs), bipolar androgen therapy, and combination strategies to overcome AR-mediated resistance.
Top recruiting AR (Androgen Receptor) Prostate Cancer trials
Ranked by phase and US site count. See all 6 trials matched to your profile →
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Kyntra Bio
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
AstraZeneca
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Vadim S Koshkin
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Ebrahim S Delpassand
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School